Published today, our latest Annual Report and Responsible Business Report show our progress in creating value for patients and shareholders. Take a look at the highlights ⤵️ 🔗 Investors and media can read more: gsk.to/4rTabHu

Today we’re at #SLEuro discussing the importance of early intervention and its role in reducing the risk of organ damage progression for patients with lupus and lupus nephritis.

#News for #investors and #media: Today we announced the completion of our acquisition of RAPT Therapeutics, adding to our growing Respiratory, Immunology & Inflammation (RI&I) pipeline. Find out more: gsk.to/4bjpC5H

We’re on the ground at #AAAAI26, sharing our latest #RespiratoryHealth research this week. Stop by Booth 1137 to learn more 🫁

#News for #investors and #media: Today we are announcing our potential treatment for chronic hepatitis B has been accepted for regulatory review in Japan. Learn more: gsk.to/3MKpqTS

News for #Investors and #Media: Today at #CROI2026, our specialist HIV company ViiV Healthcare, presented new insights on our investigational long-acting therapies. 🔗 Find out more on our website: gsk.to/4sfUv0S#Investors

#News for #investors and #media: We’ve announced an agreement to acquire 35Pharma. Find out more: gsk.to/3ZS9thp

News for #Investors and #Media: New data published in the New England Journal of Medicine compare efficacy of different forms of HIV treatment for people with adherence challenges. 🔗 Find out more on our website: gsk.to/40fqNNh#Investors

#News for #Investors and #Media: Today we are presenting new data about one of our vaccines. Learn more: gsk.to/4bZNQ66

#News for #investors and #media: The European Commission has approved our new therapy to treat two respiratory diseases. Learn more here: gsk.to/4tzOptr

#News for #Investors and #Media: Today, we are announcing that one of our vaccines has been accepted for review by the China National Medical Products Administration. Learn more: gsk.to/4qnf6Pd

Tuberculosis is a serious and contagious lung disease, with 10 million people worldwide falling ill with it each year. New treatment options are needed, and research collaborations like our work with @dundee.ac.uk are essential to keep innovation at the forefront in the fight against TB.

#News for #investors and #media: We have announced that the European Commission has approved a new therapy for use in adults with chronic obstructive pulmonary disease (COPD). Learn more here: gsk.to/3O0TpXN

Today we announce our strong 2025 performance, driven mainly by Specialty Medicines, and reaffirm our long-term outlooks. Hear more from our CEO Luke Miels ⤵️ More information for media and investors: gsk.to/4r7A5qv $GSK #earnings

Today on #WorldNTDDay, we’re reinforcing our commitment to helping eliminate neglected tropical diseases (NTDs) through our new three-year project with the END Fund. Their expertise means they are ideally placed to deliver this project, helping towards eliminating NTDs 🙌#UniteActEliminate #EndNTDs

#News for #Investors and #Media: Today, we are announcing that one of our vaccines has been approved for an expanded indication by the European Commission (EC). Learn more: gsk.to/49XpQhi

#News for #investors and #media: We have announced that China’s health authority has approved one of our therapies for use in adults with asthma. Learn more here: gsk.to/4pQb3e1

We’ve announced an agreement to acquire RAPT Therapeutics. Find out more: gsk.to/4qwhWT9

That's a wrap on #JPM2026! We're leaving inspired and confident in our R&D momentum and the future impact of our pipeline. Our approach, built on cutting-edge innovation and industry-leading partnerships, is driving us to get ahead of disease together. Check out our highlights ⤵️ #AheadTogether

Innovation starts when we stop to listen. Patients' experiences fuel our innovation, inspiring us to help people live happier, fuller lives. 🎥 Hear from the people who drive our purpose. #AheadTogether #JPM2026 #JPM26

Heading to #JPM2026? We’re joining our investor and industry partners and sharing how our R&D momentum, pipeline progress and strategic investments are driving innovation for patients. See you there! 🔗 gsk.to/4buPbkT

#News for #Investors and #Media: The European Commission (EC) has approved a new prefilled syringe presentation of one of our vaccines. 👉 Learn more: gsk.to/3LvBgAu

#News for #investors and #media: We’ve just announced data from our pivotal phase III clinical programmes for chronic hepatitis B (CHB). This marks an important step towards addressing the global burden of CHB. Learn more: gsk.to/49HDLZM

#News for #investors and #media: A new therapy for two respiratory diseases has received approval from Japan’s health authority. Learn more here: gsk.to/3Lm8ZfI

#News for #investors and #media: We have announced that China’s health authority has approved one of our therapies for use in adults with a respiratory disease. Learn more here: gsk.to/4jqC3PO

Happy New Year from all of us! 🎉 As we step into 2026, our commitments remain strong. We're excited to continue on our journey to get ahead of disease together. What are you looking forward to achieving in 2026?

Season’s greetings from us at GSK to you! 🎄 May your day be filled with peace, happiness and special moments shared with those closest to you ✨

From our network to yours, we’re wishing you a happy holiday season from across the globe! Dive into the festive spirit and hear directly from our manufacturing teams who ensure our vital medicines and vaccines reach patients, even during this special time of year.👇

A new therapy for a respiratory disease has received approval today from the US Food and Drug Administration (FDA). For more information, visit: gsk.to/3KOUZLg

We're leaving #ASH25 filled with even more inspiration and determination to bring innovative treatment options to patients living with challenging blood cancers. Watch to see how our team engaged at this year’s meeting! 🎥 🩸

#News for #Media and #Investors: Today, we are announcing that the UK Medicines and Healthcare products Regulatory Agency (MHRA) has approved a new therapy to treat two respiratory diseases. For more information, visit: www.gsk.com/en-gb/

At The Washington Post Live Post Next: The Future of Cancer event, Hesham Abdullah, Global Head of Oncology R&D shared what’s inspiring our vision to advance innovative research so those living with cancer can do more of what they love with those they care about most. Watch the video bit.ly/4qcE6ZT

We’re committed to uncovering the secrets behind disease biology through a new partnership with the Teichmann Lab at the Cambridge Stem Cell Institute called the Human Cell Atlas. Click to find out how this new partnership impacts drug discovery: gsk.to/4pAUhjW

#News for #investors and #media: We’re excited to share that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) has recommended the approval of two potential biologic treatments across three respiratory conditions. Learn more: gsk.to/48MZ1M2#News

#News for #investors and #media: The European Medicines Agency’s CHMP have issued a positive opinion on the expansion to a younger population for one of our vaccines. Access our website here: gsk.to/4aLrWTg

#News for #Media and #Investors: Today, we are announcing that one of our oral anti-infectives has been approved by the FDA. Learn more: www.gsk.com#News#Media

#News for #Investors and #Media: Today we announced that the Food and Drug Administration (FDA) has granted Orphan Drug Designation to an investigational antibody-drug conjugate in our oncology pipeline. Learn more here: gsk.to/4rFbiuy

Globally, more than 1 million people are diagnosed with a blood cancer each year. Through our latest research programmes, we are innovating for patients with blood cancers to help address their unmet needs. Watch to learn more. #ASH25

Outsmarting cancer demands focus 🔍 That’s why we’re channelling our science and technology where it can make the biggest difference for people living with cancer. Catch us at #ASH25 this weekend!

Big news for U.S. innovation! We've officially opened our new Vaccine & Infectious Disease R&D HQ in Boston's Cambridge Park Drive. This expanded space is central to our 5-year investment in the U.S., driving faster, better innovation for patients globally.

We’re looking forward to being on the ground at #ASH25 this weekend, presenting our latest progress in blood cancer research. What are you most excited for during this year’s congress? 👇

#News for #investors and #media: We are pleased to present new data from our #bloodcancer pipeline and portfolio at #ASH25. Learn more: gsk.to/4oKX2xX#News

2000 ➡️ 2025: celebrating 25 years of partnership with the @who.int on the Global Programme to Eliminate Lymphatic Filariasis (GPELF). 🔗 Find out more about the impact of the GPELF, here: gsk.to/4iwJ2X4

“More years in life, and more life in those years." That's what drives our research for people living with multiple myeloma 🧡 Our GSK experts explore what multiple myeloma is, the challenges patients face, and the potential impact of our research. 🎥 Watch the conversation: bit.ly/4rfYhaC

For Covid-19 and influenza, the risks are well-known but many people underestimate respiratory syncytial virus, or RSV. 🔗 Find out who is most at risk and how they can protect themselves: gsk.to/4icL4eL

80 years after the Nobel Prize for penicillin, antimicrobial resistance is one of societies toughest challenges. GSK, the Fleming Initiative, and the @ineosoxford.bsky.social hosted leaders at the Royal Society of Medicine to advance the global response.

Every day infections are becoming harder to treat. The solutions exist. The challenge is acting fast enough, together, to make them count. Hear from experts from across science and healthcare on how we can get ahead of AMR if we act together, now.

COPD affects over 390 million people globally, significantly impacting patients like Val and their families. This #WorldCOPDDay2025 highlights the urgent need for earlier intervention to improve lives.

We’re announcing a major research programme with the Fleming Initiative to find new ways to get ahead of #AMR. We’re combining scientific expertise with cutting-edge AI technology, including funding for around 50 dedicated UK scientific and academic positions: gsk.to/4r4CrqD

Living with blood cancer often means lifelong treatment, frequent hospital visits, and managing challenging side effects. But what if there are more ways to improve both care and quality of life? 🔗 Read more: bit.ly/43z2Brb